
Acutus Medical AFIB
Quarterly report 2024-Q3
added 11-14-2024
Acutus Medical Book Value 2011-2025 | AFIB
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Acutus Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -879 K | 75 M | 106 M | 127 M | -226 M | -132 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 127 M | -226 M | -8.53 M |
Quarterly Book Value Acutus Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.3 M | -4.8 M | -4.02 M | -879 K | 31.7 M | 43.7 M | 60.5 M | 75 M | 57.8 M | 76.7 M | 68.8 M | 106 M | 134 M | 75.9 M | 100 M | 127 M | 127 M | 127 M | 127 M | 27.5 M | 27.5 M | 27.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | -10.3 M | 63.6 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.86 | -3.26 % | $ 134 M | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Abiomed
ABMD
|
1.33 B | - | - | $ 17.2 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 307.92 | -1.93 % | $ 8.69 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 45.13 | -2.67 % | $ 6.72 K | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Abbott Laboratories
ABT
|
81.4 B | $ 125.1 | 1.48 % | $ 218 B | ||
|
Boston Scientific Corporation
BSX
|
39.4 B | $ 92.34 | 0.64 % | $ 136 B | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 2.56 | 8.94 % | $ 95.5 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 0.92 | -4.72 % | $ 14.8 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 96.35 | -1.06 % | $ 1.22 B | ||
|
OrthoPediatrics Corp.
KIDS
|
355 M | $ 17.7 | -3.46 % | $ 408 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
1.32 B | $ 62.79 | -1.82 % | $ 3.41 B | ||
|
Pulmonx Corporation
LUNG
|
85.8 M | $ 2.53 | 0.86 % | $ 99 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
InMode Ltd.
INMD
|
704 M | $ 14.56 | 0.76 % | $ 1.15 B | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 9.88 | 0.05 % | $ 709 M | ||
|
Myomo
MYO
|
6.36 M | $ 1.06 | -1.85 % | $ 7.47 M | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.55 B | $ 13.41 | -4.56 % | $ 1.03 B | ||
|
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | ||
|
Align Technology
ALGN
|
3.85 B | $ 165.15 | 0.78 % | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
81.2 M | $ 1.07 | -3.18 % | $ 110 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 12.81 | -1.23 % | $ 346 M | ||
|
Orthofix Medical
OFIX
|
503 M | $ 15.51 | -1.27 % | $ 591 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 14.86 | -0.03 % | $ 97.4 M | ||
|
AxoGen
AXGN
|
104 M | $ 30.33 | 1.15 % | $ 1.34 B | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
963 M | $ 40.78 | 2.33 % | $ 1.26 B | ||
|
LENSAR
LNSR
|
18.6 M | $ 11.48 | -0.17 % | $ 132 M |